Ex Vivo News and Research

RSS
Novel peptide-drug conjugate enhances the efficacy of immunotherapy in preclinical cancer models

Novel peptide-drug conjugate enhances the efficacy of immunotherapy in preclinical cancer models

First of its kind ‘living medicine’ designed to treat antibiotic-resistant bacteria on medical implants

First of its kind ‘living medicine’ designed to treat antibiotic-resistant bacteria on medical implants

Novel strategy for in vitro cell-selective protection has potential for use in adoptive cell therapy

Novel strategy for in vitro cell-selective protection has potential for use in adoptive cell therapy

Study reports on ex vivo drug delivery system for delivering MSCs to kidney disease patients

Study reports on ex vivo drug delivery system for delivering MSCs to kidney disease patients

Solar exposure guidelines for optimal vitamin D synthesis may need to be revised, study suggests

Solar exposure guidelines for optimal vitamin D synthesis may need to be revised, study suggests

New 3D pancreatic cancer model could be used to develop and test targeted treatments

New 3D pancreatic cancer model could be used to develop and test targeted treatments

Study points to a possible new approach for treating MRSA superbug

Study points to a possible new approach for treating MRSA superbug

Antiviral compound RG10 acts via intracellular SARS-CoV-2-ER dynamics

Antiviral compound RG10 acts via intracellular SARS-CoV-2-ER dynamics

New artificial blood vessel platform for predicting organ transplant rejection

New artificial blood vessel platform for predicting organ transplant rejection

Durable highly protective T cell response to AAV-spike vaccine against COVID-19 pneumonia in mice

Durable highly protective T cell response to AAV-spike vaccine against COVID-19 pneumonia in mice

Response to a third SARS-CoV-2 vaccine dose amongst immunocompromised

Response to a third SARS-CoV-2 vaccine dose amongst immunocompromised

Study offers new insights on coronary microvascular dysfunction

Study offers new insights on coronary microvascular dysfunction

Study shows COVID-19 organ-specific outcomes depend on anti-spike glycoprotein antibodies

Study shows COVID-19 organ-specific outcomes depend on anti-spike glycoprotein antibodies

Study associates feelings of discrimination and low status with long COVID-19 symptoms

Study associates feelings of discrimination and low status with long COVID-19 symptoms

Can memory T cell responses to seasonal coronaviruses protect against severe COVID-19?

Can memory T cell responses to seasonal coronaviruses protect against severe COVID-19?

Researchers discover new class of drugs that inhibits a 'master switch' in mantle cell lymphoma

Researchers discover new class of drugs that inhibits a 'master switch' in mantle cell lymphoma

KIYATEC’s test results accurately predict treatment response in recurrent high-grade glioma patients

KIYATEC’s test results accurately predict treatment response in recurrent high-grade glioma patients

Large-scale expansion of spike-reactive T cells feasible after COVID-19 vaccination

Large-scale expansion of spike-reactive T cells feasible after COVID-19 vaccination

Depleting SIRPα-deficient in macrophages activate tumor antigen-specific cytotoxic T cells

Depleting SIRPα-deficient in macrophages activate tumor antigen-specific cytotoxic T cells

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.